NCT07587723招募中不适用
Real-world Treatment Patterns and Outcomes of Eltrombopag in Patients With Primary Immune Thrombocytopenia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 150
- 试验地点
- 1
研究概览
简要总结
This study aims to describe the treatment patterns and clinical outcomes of treatment with eltrombopag in primary immune thrombocytopenia (ITP) patients treated with prior corticosteroid therapy.
This study will use secondary data provided by health care professionals (HCPs) for a sample of primary ITP patients, and primary data from a structured HCP survey. Data will be collected from HCPs working in various clinical centers across the United States (US), United Kingdom (UK), and Germany.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HCP inclusion criteria:
- •A licensed HCP (e.g., internal medicine specialist, hematologist, hematologist-oncologist or immunologist etc.) involved in the management of adult patients with primary ITP.
- •Actively involved in treatment decision-making for primary ITP patients at the time of the study.
- •Have a minimum of 3 years of experience managing patients with primary ITP.
- •Currently, managing an average of at least 2 adult primary ITP patients per month, including those treated with eltrombopag.
- •Able and willing to complete a web-based survey (approximately 60 to 70 minutes) and abstract data from 2 eligible patient charts.
- •Practicing in one of the study countries (US, UK, or Germany).
- •Have access to a computer or mobile device with internet connectivity to complete the survey.
- •Not listed as inactive or retired in the panel database.
- •Patient-level inclusion criteria:
- •Confirmed diagnosis of primary ITP.
- •Aged ≥18 years at the time of diagnosis.
- •Received first-line corticosteroid therapy (with or without intravenous immune globulin [IVIg]).
- •Initiated eltrombopag treatment (with or without corticosteroids) as first non-steroidal ITP treatment between 01 January 2020 and 31 December
- •Have at least 6 months of follow-up data available after the index date (unless deceased within that period).
排除标准
- •HCP exclusion criteria:
- •Currently employed by a pharmaceutical company or regulatory authority involved in the approval or marketing of treatments for primary ITP.
- •Unable to provide data for patients who meet the study's inclusion criteria.
- •Not currently managing patients with primary ITP or are not involved in treatment decisions for these patients.
- •Patient-level exclusion criteria:
- •1. Diagnosis of Evans syndrome, secondary ITP, or non-immune thrombocytopenia.
研究组 & 干预措施
Eltrombopag Cohort
Adult patients diagnosed with primary ITP who initiated eltrombopag treatment between 01 January 2020 and 31 December 2024 following corticosteroid treatment.
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic AnemiaAplastic AnemiaNCT07415083Novartis Pharmaceuticals13
尚未招募
2 期
Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke ThrombectomyIschemic StrokeNCT07511543Population Health Research Institute100
尚未招募
不适用
Risk factors and prognosis of adult patients presenting with bleeding from upper gastrointestinal tractCTRI/2024/06/069484JLN Medical College and Hospital60
招募中
不适用
Head of Bed After Ischemic Stroke Thrombectomy (HoBIT)StrokeNCT07367633Population Health Research Institute2,240
撤回
2 期
CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAASevere Aplastic Anemia (SAA)Transfusion-dependent Non-severe Aplastic AnemiaNCT07523009Peking Union Medical College Hospital43